IMU-838 and Oseltamivir in the Treatment of COVID-19 (IONIC)

• ClinicalTrials.gov Identifier: NCT04516915
• Recruitment Status: Active, not recruiting
• First Posted: August 18, 2020
• Last Update Posted: July 12, 2022
• Sponsor: University Hospitals Coventry and Warwickshire NHS Trust
• Collaborators: Immunic AG; University of Warwick; MODEPHARMA
• Information provided by (Responsible Party): University Hospitals Coventry and Warwickshire NHS Trust

Tracking Information

• First Submitted Date: August 10, 2020
• First Posted Date: August 18, 2020
• Last Update Posted Date: July 12, 2022
• Actual Study Start Date: June 15, 2020
• Actual Primary Completion Date: May 20, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 17, 2020)

To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) vs. Oseltamivir alone in adult subjects with COVID-19 [ Time Frame: 14 days ]

Time-to-clinical improvement; defined as the time from randomisation to a 2-point improvement on the world health organizations 9-point ordinal scale (ranging from 0-8; 0 being no evidence of clinical infection and 8 being death), discharge from hospital, or death (whichever occurs first)

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: August 17, 2020)

• To evaluate safety (number of adverse events) and tolerability (laboratory abnormalities) of IMU 838 + Oseltamivir vs. Oseltamivir alone in adult subjects with COVID-19. [ Time Frame: 28 days ]
  Incidence of Adverse events (AEs) and serious adverse events (SAEs), including COVID-19 worsening and incidence of laboratory abnormalities (defined as a 1.5x increase in liver function test results (total protein, albumin, bilirubin, alkaline phosphotase and ALT) from screening).
• To determine the effects of IONIC Intervention on improvement of at least two points in clinical status scale (from 0 to 8; with 8 being no evidence of clinical infection and 8 being death) [ Time Frame: 28 days ]
  Proportion of patients with two-point change on WHO ordinal scale at Day 7 and 28
• To assess the effects of IONIC Intervention vs. Oseltamivir on the need for invasive ventilation, renal replacement therapy or ECMO [ Time Frame: 14 days ]
  Proportion of patients free of invasive ventilation, renal replacement therapy or ECMO at Day 7 and 14
• To assess the effects of IONIC Intervention vs. Oseltamivir on the length of hospital and intensive care unit (ICU) stay [ Time Frame: 28 days ]
  To assess the effects of IONIC Intervention vs. Oseltamivir on the length of hospital and intensive care unit (ICU) stay
• To assess the effects of IONIC Intervention vs. Oseltamivir on the time from treatment initiation to death [ Time Frame: 28 days ]
  Mortality at day 28 and time from treatment initiation to death

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: IMU-838 and Oseltamivir in the Treatment of COVID-19
• Official Title: Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19
• Brief Summary: To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) and standard care vs. Oseltamivir and standard care in adult subjects with coronavirus disease (COVID-19)

Detailed Description

The IONIC Protocol describes an overarching trial design to provide reliable evidence on the efficacy of IMU-838 (vidofludimus calcium) when delivered in combination with an antiviral therapy (Oseltamivir) [IONIC Intervention] for confirmed or suspected COVID-19 infection in adult patients receiving usual standard of care.

At present, there are no known treatments for COVID-19. Whilst, the anticipated scale of the epidemic is such that hospitals, and particularly intensive care facilities, may be massively overstretched. As described by a few models of pandemic spread, up to 50% of the adult population may fall sick over a period of 8-12 weeks, of whom around 10% may require hospitalisation. This figure could imply nearly 2 million hospital admissions. Considering this scenario, therapies which may only have a moderate impact on survival or on hospital resources could be worthwhile.

Critically, the present trial design has been developed with consideration of the front-line hospital staff working within an overstretched care system in these unprecedented times. To minimise their burden the protocol is deliberately flexible so that it is suitable for a wide range of settings, allowing:

• a broad range of patients to be enrolled (patient pathway, disease stage or mode of diagnosis)
• Additional sub-studies may be added to provide more detailed information on side effects or sub-categorisation of patient types but these are not the primary objective and are not required for participation.
• To be able to include more sites: the investigators will initiate the trial as a single centre (UHCW) and more sites invited to participate according to the emerging evidence
• The investigator have included 'Exploratory and Secondary objectives' in the protocol however, in consideration of the circumstances the research activities will emulate investigations performed as per standard care/routines care to minimise any burden on the delivery teams.

This is a Phase 2b, randomised, parallel-group, open-label study to assess the efficacy and safety of an oral dose of IMU-838 (22.5 mg twice daily [45 mg/day]) plus Oseltamivir (75mg twice daily [150mg/day]) (IONIC Intervetion) or Oseltamivir alone (75mg twice daily) in hospitalised patients with COVID-19.

• Study Type: Interventional
• Study Phase: Phase 2

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Prospective, Randomized, Parallel-Group, Open-Label Study

Masking: None (Open Label)
Primary Purpose: Treatment

• Condition: Covid 19

Intervention

• Drug: IMU-838
  IMU-838 twice daily at 22.5mg doses for 14 days
  Other Name: Intervention Arm
• Drug: Oseltamivir
  Oseltamivir twice daily at 75mg doses for 14 days
  Other Name: Control arm

Study Arms

• Experimental: IMU-838 + Oseltamivir
  Loading dose of IMU-838 followed by 22.5mg BID plus Oseltamivir (75mg BID) for 14 days
  Interventions:

  • Drug: IMU-838
  • Drug: Oseltamivir
• Active Comparator: Oseltamivir
  Oseltamivir (75mg BID) for 14 days
  Intervention: Drug: Oseltamivir

• Publications *: Sharma K, Berry L, Vryonis E, Ali A, Lara B, Noufaily A, Parsons N, Bradley C, Haley B, Tabuso M, Arasaradnam RP. Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol. BMJ Open. 2022 Nov 17;12(11):e055205. doi: 10.1136/bmjopen-2021-055205.

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: July 8, 2022): 38
• Original Estimated Enrollment (submitted: August 17, 2020): 120
• Estimated Study Completion Date: September 2022
• Actual Primary Completion Date: May 20, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• 1. Male or non-pregnant female patients at least 18 years old 2. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection, either:

  • Confirmed cases: prospective participants who test positive to a validated specific SARS-CoV-2 nucleic acid test or has the virus identified by electron microscopy or viral culture, as per local trust policy ≤ 7 days before randomisation.
  • Probable/Suspected case: prospective participants who may have been in contact with a confirmed case of COVID-19, AND have mild to severe COVID-19 clinical symptoms AND radio-graphic evidence* of pulmonary infiltrates consistent with COVID-19 disease 3. Moderate to severe COVID-19 requiring hospitalisation defined as: a) Clinical status category 3-5 (inclusive) on the 7-point clinical status category scale as proposed by the World Health Organisation (WHO) master protocol: I. Category 3: hospitalized, no oxygen therapy II. Category 4: hospitalized, oxygen by mask or nasal prongs III. Category 5: hospitalized, non-invasive ventilation or high-flow oxygen *where routinely available, no tests will be requested for research purpose

Exclusion Criteria

Therapy Exclusion Criteria:

Use of the following concomitant medications is prohibited at Screening Visit and throughout the duration of the trial:

1. Use of Oseltamivir for more than 48 hrs prior to the first treatment dose
2. Use of antiviral drugs (e.g. nucleoside analogue reverse-transcriptase inhibitors, protease inhibitors, etc.)
3. History of long-term or concurrent use of mycophenolate mofetil, methotrexate exceeding 17.5 mg weekly
4. Chloroquine or hydroxychloroquine
5. Any medication known to significantly increase urinary elimination of uric acid, in particular lesinurad as well as uricosuric drugs such as probenecid
6. Treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, sorafinib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib
7. Any drug significantly restricting water diuresis, in particular vasopressin and vasopressin analogues
8. Use of rosuvastatin at daily doses higher than 10 mg

Medical History of Concomitant Disease Exclusion Criteria

• Allergic or hypersensitivity to the IMU-838, Oseltamivir, or any of the ingredients
• Pregnant or breastfeeding or with intention to become pregnant during the study
• Participants who cannot take trial medication orally at presentation
• Undergoing active chemotherapy or radiotherapy.
• If the attending clinician believes that there is a specific contra-indication to the IONIC intervention.
• Patient has a medical or concomitant disease history preventing them from participating
• Critical patients whose expected survival time < 48-72 hours
• Evidence of pancytopenia or immunosuppression
• Any contraindication to Oseltamivir or standard of care

Presence of the following laboratory values at Screening Exclusion Criteria

• Platelet count <100,000/mm³ (<100 x 109/L)
• Total bilirubin > 2 x ULN or ALT or GGT > 5 x ULN
• Elevated indirect (unconjugated) bilirubin >1.2 x ULN (i.e. >1.1 mg/dL)
• Serum uric acid levels at Screening Visit >1.2 x ULN (for women >6.8 mg/dL, for men >8.4 mg/dL)
• Renal impairment defined as estimated glomerular filtration rate ≤45 mL/min/1.73m²
• Decompensated liver cirrhosis (Child-Pugh score B and C)
• History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association [NYHA] class 3 or 4)
• Cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA class 4: Cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
• History or presence of any major medical or psychiatric illness (such as severe depression, psychosis, bipolar disorder), history of suicide attempt, or current suicidal ideation, if any of those conditions in the opinion of the investigator could create undue risk to the patient or could affect adherence with the trial protocol

COVID-19 related exclusion criteria

• Participation in any other interventional clinical trial for an experimental treatment for COVID-19

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 90 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United Kingdom

Administrative Information

• NCT Number: NCT04516915
• Other Study ID Numbers: RA486120
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: University Hospitals Coventry and Warwickshire NHS Trust
• Original Responsible Party: Same as current
• Current Study Sponsor: University Hospitals Coventry and Warwickshire NHS Trust
• Original Study Sponsor: Same as current

Collaborators

• Immunic AG
• University of Warwick
• MODEPHARMA

• Investigators: Not Provided
• PRS Account: University Hospitals Coventry and Warwickshire NHS Trust
• Verification Date: July 2022